Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach (Review)

Experimental and Therapeutic Medicine

Volumn 2, Issue 2, 2011, Pages 173-180

  Binaschi, Monica ^a   Simonelli, Cecilia ^b   Goso, Cristina ^a   Bigioni, Mario ^a   Maggi, Carlo Alberto ^a  

^a Department of Pharmacology ^*  (Italy)

^b Menarini Ricerche SpA   (Italy)

Author keywords

Abagovomab; CACA 125; Maintenance therapies; Ovarian cancer

Indexed keywords

ABAGOVOMAB; ALPHA INTERFERON; ALTRETAMINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENZASTAURIN; EPIRUBICIN; ERLOTINIB; OREGOVOMAB; PACLITAXEL; PLACEBO; SORAFENIB; TAMOXIFEN; VASCULOTROPIN;

CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER STEM CELL; CANCER SURGERY; CANCER SURVIVAL; CELL INTERACTION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; INTESTINE PERFORATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE;

EID: 79551646460     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.192     Document Type: Review

References (59)

1. Bast RC, Hennessy B and Lills GB: The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9: 415-428, 2009.
2. Yap TA, Carden CP and Kaye SB: Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9: 167-181, 2009.
3. Menon U, Gentry-Maharaj A, Hallett R, et al: Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10: 327-340, 2009.
4. Visintin I, Feng Z, Longton G, et al: Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14: 1065-1072, 2008.
5. Yurkovetsky Z, Skates S, Lomakin A, et al: development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 28: 2159-2166, 2010.
6. Kulasingam V, Pavlou MP and Diamandis EP: Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer 10: 371-378, 2010.
7. Paulsen T, Kjaerheim K, Kaern J, Tretli S and Trope C: Improved short-term survival for advanced ovarian, tubal, peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer 16: 11-17, 2006.
8. Engelen MJ, Kos HE, Willemse PH, et al: Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 106: 589-598, 2006.
9. Earle CC, Schrag D, Neville BA, et al: Effect of surgeon speciality on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 98: 172-180, 2006.
10. Fung ET: A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem 56: 327-329, 2010.
11. Moore RG, McMeekin DS, Brown AK, et al: A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112: 40-46, 2009.
12. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D and Burger RA: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21: 3183-3195, 2003.
13. Dean M, Fojo T and Bates S: Tumor stem cells and drug resistance. Nat Rev Cancer 5: 275-284, 2005.
14. Szotek PP, Pieretti-Vanmarcke R, Masakiatos PT, et al: Ovarian cancer side population defines cells with stem cell-like characteristics and Mullarian inhibiting substance responsiveness. Proc Natl Acad Sci USA 103: 11154-11159, 2006.
15. Alvero AB, Chen R, Fu H, et al: Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance. Cell Cycle 8: 158-161, 2009.
16. Bapat SA, Mali AM, Koppikar CB and Kurrey NK: Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65: 3025-3029, 2005.
17. Zhang S, Balch C, Chan MW, et al: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68: 4311-4320, 2008.
18. Baba T, Covery PA, Matsumura N, et al: Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 28: 209-218, 2009.
19. Moserle L, Indraccolo S, Ghisi M, et al: The side population of ovarian cancer cells is a primary target of INF-α antitumor effects. Cancer Res 68: 5658-5668, 2008.
20. Hu L, McArthur C and Jaffe RB: Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 102: 1276-1283, 2010.
21. Leizer AL, Alvero AB, Fu HH, et al: Regulation of inflammation by the NF-κB pathway in ovarian cancer stem cells. Am J Reprod Immunol: Sept. 5, 2010 (E-pub ahead of print).
22. Hall GD, Brown JM, Coleman RE, et al: Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. Br J Cancer 91: 621-626, 2004.
23. Widschwendter M, Fiegl H, Egle D, et al: Epigenetic stem cell signature in cancer. Nat Genet 39: 157-158, 2006.
24. Jones PA and Baylin SB: The epigenomic of cancer. Cell 128: 683-692, 2007.
25. Ito K, Bernardi R and Pandolfi PP: A novel signalling network as a critical rheostat for the biology and maintenance of the normal stem cell and the cancer initiating cell. Curr Opin Genet Dev 19: 51-59, 2009.
26. Park JT, Chen X, Tropè CG, Davidson B, Shihle M and Wang TL: Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol 177: 1087-1094, 2010.
27. Lis R, Touboul C, Mirshahi P, et al: tumor associated mesenchymal stem cells protects ovarian cancer cells from hyperthermia through CXCL12. Int J Cancer 128: 715-725, 2010.
28. Rothenberg ML, Liu PY, Wilczynski S, et al: Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: A Southwest Oncology Group Trial (SWOG-9326). Gynecol Oncol 82: 317-322, 2001.
29. Bertelsen K, Jakobsen A, Stroyer I, et al: A prospective randomized comparison of 6 and 12 courses of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 49: 30-36, 1993.
30. Lambert HE, Rustin GJ, Gregory WM and Nelstrop AE: A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. Ann Oncol 8: 327-333, 1997.
31. Hakes TB, Chalas E, Hoskins WJ, et al: Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 45: 284-289, 1992.
32. Barakat RR, Sabbatini P, Bhaskaran D, et al: Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol 20: 694-698, 2002.
33. Markman M, Liu PY, Wilczynski S, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21: 2460-2465, 2003.
34. Perez-Gracia JL and Carrasco EM: Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol Oncol 84: 201-209, 2002.
35. Berek J, Taylor P, McGuire W, Mary Smith L, Schultes B and Nicodemus CF: Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 27: 418-425, 2009.
36. Ozols RF: Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. J Clin Oncol 13: 2451-2453, 2003.
37. Wong C, Wellman TL and Lounsbury KM: VEGF and HIF-1α expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol 91: 513-517, 2003.
38. Yamamoto S, Konishi I, Mandai M, et al: Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76: 1221-1227, 1997.
39. Brustamann H: Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis. Gynecol Oncol 95: 16-22, 2004.
40. Kraft A, Weindel K, Ochs A, et al: vascular endothelial growth factor in the sera and effusion of patients with malignant and non malignant disease. Cancer 85: 178-187, 1999.
41. Mesiana S, Ferrara N and Jaffe RB: Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascite formation by immunoneutralization. Am J Pathol 153: 1249-1256, 1998.
42. Mabuchi S, Terai Y, Morishige K, et al: Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res 14: 7781-7789, 2008.
43. Burger RA, Sill MW, Monk BJ, Greer BE and Sorosky JI: phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 5165-5171, 2007.
44. Cannistra SA, Matulonis UA, Penson RT, et al: phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25: 5180-5186, 2007.
45. Richardson DL, Backes FJ, Seamon LG, et al: Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol 111: 461-466, 2008.
46. Kaye SB: Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour? J Clin Oncol 25: 5150-5152, 2007.
47. Pàez-Ribes M, Allen E, Hudock J, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231, 2009.
48. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG and Kerbel RS: Accelerated metastasis after short term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239, 2009.
49. Loges S, Mazzone M, Hohensinner P and Carmeliet P: Silencing or fueling metastasis with VEGF inhibitors: angiogenesis revisited. Cancer Cell 15: 167-170, 2009.
50. Berchuck A, Rodriguez GC, Kamel A, et al: Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 164: 669-674, 1991.
51. Morishige K, Kurachi H, Amemiya K, et al: Involvement of transforming growth factor alpha/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer. Cancer Res 51: 5951-5955, 1991.
52. Bartlett JM, Langdon SP, Simpson BJ, et al: The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 73: 301-306, 1996.
53. Gordon AN, Finkler N, Edwards RP, et al: Efficacy and safety of erlotinib HCL, an epidermal growth factor receptor (HER1/ EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 15: 785-792, 2005.
54. Braly P, Nicodemus CF, Chu C, et al: the immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous orego-vomab chemoimmunotherapy in advanced ovarian cancer. J Immunother 32: 54-65, 2009.
55. Jerne NK: Towards a network theory of the immune system. Ann Immunol 125C: 373-389, 1974.
56. Wagner U, Köhler S, Reinartz S, et al: Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res 7: 1154-1162, 2001.
57. Reinartz S, Köhler S, Schlebusch H, et al: vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 10: 1580-1587, 2004.
58. Pfisterer J, du Bois A, Sehouli J, et al: the anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol 17: 1568-1577, 2006.
59. Sabbatini P, Dupont J, Aghajanian C, et al: phase i study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 12: 5503-5510, 2006.